GlassScriptPhysician profile
James A Butler
NPI 1295849222
$6,332.84
in general payments reported to CMS, 2019-2025
28 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $173 · 2021: $517 · 2022: $632 · 2023: $1,190 · 2024: $1,217 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.86 | 2019-2025 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $900.48 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $788.74 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $483.06 | 2019-2024 | Zeposia |
| Janssen Biotech, INC. | $450.68 | 2019-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $232.17 | 2019-2023 | Rebyota |
| Lilly USA, LLC | $203.91 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $203.21 | 2022-2024 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $178.03 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $157.14 | 2019-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $131.11 | 2021 | |
| Echosens North America, INC. | $121.00 | 2023 | Fibroscan |
| Genzyme Corporation | $113.64 | 2022-2025 | |
| Pfizer INC. | $98.93 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $59.32 | 2022-2023 | |
| Ardelyx, INC. | $49.30 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $46.22 | 2023-2025 | Ocaliva |
| Braintree Laboratories, INC. | $42.68 | 2019-2023 | Sutab |
| Merck Sharp & Dohme LLC | $31.92 | 2020-2022 | |
| Daiichi Sankyo INC. | $29.58 | 2024 | Injectafer |
| Stryker Corporation | $28.78 | 2025 | Neptune |
| Cumberland Pharmaceuticals, INC. | $26.90 | 2025 | Kristalose |
| Biocon Biologics INC | $20.60 | 2025 | Yesintek |
| Madrigal Pharmaceuticals | $19.09 | 2025 | Rezdiffra |
| Ucb, INC. | $17.80 | 2019 | |
| Allergan, INC. | $12.83 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.